نتایج جستجو برای: fulvestrant
تعداد نتایج: 782 فیلتر نتایج به سال:
Cross-resistance to molecules used in endocrine therapy is among the main challenges in the treatment of estrogen receptor-alpha (ERalpha) positive breast cancer. In this study, we used two different cell models of resistance to anti-estrogens: MVLN/CL6.7 cells and VP229/VP267 cells selected after exposure to tamoxifen respectively in vitro and in vivo to characterize a phenotype rarely observe...
FOXM1 (12p13.33) GLI1, doxorubicin, NRAS, fulvestrant, butyric acid, FGF7, CDKN1A, YY1, MSA, vitamin D3, TNFSF11, IL6, CDC2 CDC25B, CENPA, AURKB, CCNA2, CCNF, CENPB, BIRC5, CCNB1, CDKN1A, ESR1, ADAM17, GLB1 Controls progression into S phase; regulates genes required for mitotic entry; liver development. Reduced hepatoblast and cardiomyocyte mitosis, ventricular hypoplasia. Die perinatally. Upre...
Abstract Introduction Endocrine therapy (ET), specifically aromatase inhibitors (AIs) that lower estrogen to subphysiologic levels and receptor (ER) degraders non-selectively negatively impact ER function, may induce genitourinary syndrome of menopause (GSM) in breast cancer patients. Novel therapies with positive impacts are desirable. Lasofoxifene reduced incidence a large clinical study, whi...
The development of targeted therapies for antiestrogen-resistant breast cancer requires a detailed understanding of its molecular characteristics. To further elucidate the molecular events underlying acquired resistance to the antiestrogens tamoxifen and fulvestrant, we established drug-resistant sublines from a single colony of hormone-dependent breast cancer MCF7 cells. These model systems al...
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors (palbociclib, abemaciclib, ribociclib) are used to treat human epithelial growth factor receptor (HER)-2 negative hormone (HR) positive advanced breast cancer in combination with aromatase (letrozole, anastrozole) or an estrogen antagonist (fulvestrant). Administration of these drugs frequently causes severe side effects, such as neutropenia d...
Cost-effectiveness of everolimus+exemestane as compared to fulvestrant was assessed in terms of the incremental cost per life year (LY) gained, from a Portuguese National Health Service (NHS) perspective. Next to main therapeutic drug costs, other healthcare costs included costs for medical visits, complementary diagnostic procedures, surgery, inpatient visits, additional therapy and end-of-lif...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید